Back to results

EL625 in Persistent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Primary Purpose

Lymphoma, Small Lymphocytic, Leukemia, Lymphocytic, Chronic

Status

Terminated

Phase

Phase 2

Locations

United States

Study Type

Interventional

Intervention

cenersen sodium

Rituximab

Cyclophosphamide

Fludarabine

About this trial

This is an interventional treatment trial for Lymphoma, Small Lymphocytic focused on measuring Small Lymphocytic Lymphoma, Chronic Lymphocytic Leukemia, EL625, cenersen

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

Patients with a diagnosis of CLL/SLL who have received at least one prior treatment regimen and have persistent disease (i.e. any evidence of active disease). Patients with a chromosome 17 abnormality or a p53 mutation of any type may be enrolled without having received prior treatment.
Patients must be 18 years of age or older.
Patient has an estimated or measured creatinine clearance ≥30 ml/min at study enrollment.
AST, ALT, total bilirubin < than 2.5 times the upper limit of normal.
WBC > 1.5; ANC >500; Plt >50,000 unless documented as due to disease
ECOG performance status of 0-2.
Voluntary written informed consent before performance of any study-related procedure not part of normal medical care.
Female subject is either post-menopausal or surgically sterilized or willing to use an acceptable method of birth control (i.e., a hormonal contraceptive, intra-uterine device, diaphragm with spermicide, condom with spermicide, or abstinence) for 2 weeks after administration of the study drug.
Male subject agrees to use an acceptable method for contraception for the duration of the study therapy and for 2 weeks after administration of study drug.

Exclusion Criteria:

Female who is pregnant or lactating.
Serious medical or psychiatric illness likely to interfere with participation in this clinical study.
Patients with another malignancy within the last three years (from documentation of remission) other than basal or squamous cell skin cancer, resected early stage prostate cancer not requiring systemic treatment or CIS of the cervix or fully treated early stage prostate cancer.
Significant cardiac or vascular events within 6 months: acute MI, unstable angina, severe peripheral vascular disease (ischemic pain at rest class 3 or worse, non-healing ulcers/wounds, congestive heart failure (NYHA class ≥ 2), uncontrolled cardiac arrhythmias, and disseminated intravascular coagulation.
Patients who are unable to refrain from taking acetaminophen
Investigational agent within 14 days of enrolling on the study.
Patients unable or unwilling to refrain from antioxidants including vitamin A, vitamin C, vitamin E, lycopene, lutein, grape seed extract, pycnogenol, green tea extract, and the like.
Patients who have received a prior allogenic stem cell transplant and have at least 2.5% donor cells still evident on engraftment studies.

Sites / Locations

Duke University Medical Center

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

all patients

Arm Description

EL625 combined with traditional chemotherapy (rituximab, fludarabine, and cyclophosphamide)

Outcomes

Primary Outcome Measures

Number of Patients With an Overall Response (Complete Response + Partial Response)

Overall Response is the total number of participants with a Complete (CR) or Partial (PR) response. CR requires the absence of lymphadenopathy, hepatomegaly or splenomegaly and constitutional symptoms and a normal CBC; bone marrow must be at least normocellular for age, with less than 30% nucleated cells being lymphocytes with no lymphoid nodules. Partial Response: requires ≥ 50% decrease in one of the following: peripheral blood lymphocyte count, lymphadenopathy, enlargement of liver and/or spleen, or bone marrow involvement by CLL AND at least one hematologic parameter met for 2 months.

Secondary Outcome Measures

Progression Free Survival

Progression is defined as at least one of the following: 1) ≥ 50% increase in the sum of the products of at least two lymph nodes one two consecutive determinations (at least one node must be ≥ 2 cm); appearance of new palpable lymph nodes, 2) ≥ 50% increase in the size of the liver and/or spleen; appearance of palpable hepatomegaly or splenomegaly, which was not previously present, 3) ≥ 50% increase in the absolute number of circulating lymphocytes to at least 5,000/µl or 4)Transformation to a more aggressive histology.

Overall Survival

Full Information

NCT ID

NCT00636155

First Posted

January 22, 2008

Last Updated

November 26, 2012

Sponsor

David Rizzieri

Collaborators

Eleos, Inc.

1. Study Identification

Unique Protocol Identification Number

NCT00636155

Brief Title

EL625 in Persistent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Official Title

A Phase II Study of EL625 in Patients in Persistent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Study Type

Interventional

2. Study Status

Record Verification Date

November 2012

Overall Recruitment Status

Terminated

Why Stopped

funding

Study Start Date

February 2008 (undefined)

Primary Completion Date

August 2011 (Actual)

Study Completion Date

May 2012 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title

Sponsor-Investigator

Name of the Sponsor

David Rizzieri

Collaborators

Eleos, Inc.

4. Oversight

Data Monitoring Committee

5. Study Description

Brief Summary

The purpose of this research study is to see if the investigational drug EL625, when combined with traditional chemotherapy (rituximab, fludarabine, and cyclophosphamide), is effective in Persistent Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)

Detailed Description

Chronic lymphocytic leukemia (CLL) and small B-cell lymphocytic lymphoma (SLL) are thought to be different manifestations of the same disease. Treatment options for CLL/SLL range from a watch and wait approach to bone marrow transplant. Currently there is no consensus on the best treatment regimen and new approaches to treatment are needed. EL625 is a 20-mer antisense molecule which binds to a coding region of exon 10 in p53 RNA transcripts. It can bind to both mutant and wild type p53. p53 is involved in regulating apoptosis and DNA repair in cells. When genetic damage occurs p53 is upregulated. As the expression of p53 increases in normal cells they are more likely to undergo apoptosis rather than cell cycle arrest and DNA repair. However in malignant cells, for a given level of DNA damage they are more likely to undergo cell cycle arrest and repair rather than apoptosis. Because EL625 is theorized to increase response to chemotherapy, we propose adding EL625 to a combination of fludarabine, cyclophosphamide and rituximab.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study

Lymphoma, Small Lymphocytic, Leukemia, Lymphocytic, Chronic

Keywords

Small Lymphocytic Lymphoma, Chronic Lymphocytic Leukemia, EL625, cenersen

7. Study Design

Primary Purpose

Treatment

Study Phase

Phase 2

Interventional Study Model

Single Group Assignment

Masking

None (Open Label)

Allocation

N/A

Enrollment

20 (Actual)

8. Arms, Groups, and Interventions

Arm Title

all patients

Arm Type

Experimental

Arm Description

EL625 combined with traditional chemotherapy (rituximab, fludarabine, and cyclophosphamide)

Intervention Type

Drug

Intervention Name(s)

cenersen sodium

Other Intervention Name(s)

EL625

Intervention Description

2.4 mg/kg/day as a continuous infusion over 24 hours starting on day one and ending on day 4

Intervention Type

Drug

Intervention Name(s)

Rituximab

Other Intervention Name(s)

Rituxan

Intervention Description

375 mg/m2 on day 2

Intervention Type

Drug

Intervention Name(s)

Cyclophosphamide

Other Intervention Name(s)

Cytoxan

Intervention Description

250 mg/m2 on days 2, 3, and 4

Intervention Type

Drug

Intervention Name(s)

Fludarabine

Other Intervention Name(s)

Fludara

Intervention Description

25 mg/m2 on days 2, 3, and 4

Primary Outcome Measure Information:

Title

Number of Patients With an Overall Response (Complete Response + Partial Response)

Description

Time Frame

every 3 cycles

Secondary Outcome Measure Information:

Title

Progression Free Survival

Description

Time Frame

5 years

Title

Overall Survival

Time Frame

5 years

10. Eligibility

Sex

All

Minimum Age & Unit of Time

18 Years

Accepts Healthy Volunteers

Eligibility Criteria

Inclusion Criteria: Patients with a diagnosis of CLL/SLL who have received at least one prior treatment regimen and have persistent disease (i.e. any evidence of active disease). Patients with a chromosome 17 abnormality or a p53 mutation of any type may be enrolled without having received prior treatment. Patients must be 18 years of age or older. Patient has an estimated or measured creatinine clearance ≥30 ml/min at study enrollment. AST, ALT, total bilirubin < than 2.5 times the upper limit of normal. WBC > 1.5; ANC >500; Plt >50,000 unless documented as due to disease ECOG performance status of 0-2. Voluntary written informed consent before performance of any study-related procedure not part of normal medical care. Female subject is either post-menopausal or surgically sterilized or willing to use an acceptable method of birth control (i.e., a hormonal contraceptive, intra-uterine device, diaphragm with spermicide, condom with spermicide, or abstinence) for 2 weeks after administration of the study drug. Male subject agrees to use an acceptable method for contraception for the duration of the study therapy and for 2 weeks after administration of study drug. Exclusion Criteria: Female who is pregnant or lactating. Serious medical or psychiatric illness likely to interfere with participation in this clinical study. Patients with another malignancy within the last three years (from documentation of remission) other than basal or squamous cell skin cancer, resected early stage prostate cancer not requiring systemic treatment or CIS of the cervix or fully treated early stage prostate cancer. Significant cardiac or vascular events within 6 months: acute MI, unstable angina, severe peripheral vascular disease (ischemic pain at rest class 3 or worse, non-healing ulcers/wounds, congestive heart failure (NYHA class ≥ 2), uncontrolled cardiac arrhythmias, and disseminated intravascular coagulation. Patients who are unable to refrain from taking acetaminophen Investigational agent within 14 days of enrolling on the study. Patients unable or unwilling to refrain from antioxidants including vitamin A, vitamin C, vitamin E, lycopene, lutein, grape seed extract, pycnogenol, green tea extract, and the like. Patients who have received a prior allogenic stem cell transplant and have at least 2.5% donor cells still evident on engraftment studies.

Overall Study Officials:

First Name & Middle Initial & Last Name & Degree

David Rizzieri, MD

Organizational Affiliation

Duke University

Official's Role

Principal Investigator

Facility Information:

Facility Name

Duke University Medical Center

City

Durham

State/Province

North Carolina

ZIP/Postal Code

27710

Country

United States

12. IPD Sharing Statement

Learn more about this trial

EL625 in Persistent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

We'll reach out to this number within 24 hrs